$TWST

Cho Dennis sold $28K of TWST

Cho Dennis (See Remarks) sold 402 shares of Twist Bioscience Corp (TWST) at $69.84 on 2026-06-08.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 10, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Because it’s a routine insider transaction without accompanying corporate news, it mainly affects sentiment rather than valuation drivers.

02

Market read

Traders may note the insider selling signal, but the disclosed value is modest and not a standalone catalyst.

03

What to watch

The transaction size is small relative to typical institutional flows, and the filing timing may not coincide with any fundamental catalyst.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10 for a 2026-06-08 sale

Background

The article is a primary-source SEC Form 4 disclosure reporting an officer’s open-market sale of Twist Bioscience shares.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience insider Dennis Cho filed an open-market sale of 402 shares at $69.8442 on 2026-06-08 (Form 4).

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with modest dollar value ($28k) and no stated linkage to a new corporate event.

Market effects

No clear read-across to biotech tools/insider behavior beyond routine governance signals.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the lack of a 10b5-1 plan doesn’t necessarily imply bearish conviction.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Dennis Cho

    Officer who sold 402 shares on 2026-06-08.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.